<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2021-6.2.11</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-2736</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group></article-categories><title-group><article-title>Перспективные диагностические маркёры рака толстой кишки</article-title><trans-title-group xml:lang="en"><trans-title>Promising Diagnostic Markers of Colon Cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8696-9562</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волков</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры онкологии, </p><p>672090,г. Чита, ул. Горького,39а</p></bio><bio xml:lang="en"><p>Teaching Assistant at the Department of Oncology,</p><p>Gorkogo str. 39a, Chita 672090</p></bio><email xlink:type="simple">vsv_19@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1665-3754</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лобанов</surname><given-names>С. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Lobanov</surname><given-names>S. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой факультетской хирургии с курсом урологии, </p><p>672090,г. Чита, ул. Горького,39а</p></bio><bio xml:lang="en"><p> Dr. Sc. (Med.), Professor, Head of the Department of Faculty Surgery with a Course of Urology, </p><p>Gorkogo str. 39a, Chita 672090</p></bio><email xlink:type="simple">slobanov15@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Читинская государственнаямедицинская академия» Минздрава России</institution></aff><aff xml:lang="en"><institution>Chita State Medical Academy</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>22</day><month>06</month><year>2021</year></pub-date><volume>6</volume><issue>2</issue><fpage>98</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волков С.В., Лобанов С.Л., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Волков С.В., Лобанов С.Л.</copyright-holder><copyright-holder xml:lang="en">Volkov S.V., Lobanov S.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/2736">https://www.actabiomedica.ru/jour/article/view/2736</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Заболеваемость раком толстой кишки (РТК) за последнее десятилетие заметно растёт в Российской Федерации, при этом около 50 % случаев выявляется на III–IV стадии болезни, когда появляется отчётливая клиническая картина заболевания. В связи с этим поиск новых методов дополнительной диагностики РТК, несомненно, является актуальным.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: определить стандартный состав аэробной пристеночной толстокишечной микробиоты и уровень цитокинов (хемокинов и факторов роста) у больных раком левой половины толстой кишки и оценить возможность использования этих данных в диагностике опухолевого процесса.</p></sec><sec><title>Методы</title><p>Методы. Исследование крови осуществлялось в день исследования с помощью двух тест-систем (BioLegend): мультиплексного набора для определения факторов роста и мультиплексного набора для определения хемокинов. Состав кишечной микробиоты определялся в биоптатах толстой кишки бактериологическим методом с использованием стандартных тест-систем StaphyTest, StreptoTest и EnteroTest.</p></sec><sec><title>Результаты</title><p>Результаты. Прослеживается рост количества Clostridium spp. и снижение Bifidobacterium spp., E. coli в толстой кишке в процессе трансформации слизистой здорового человека в злокачественную опухоль (р &lt; 0,05); выявлена чёткая тенденция как увеличения (EGF, HGF, M-CSF, PDGF-AA, PDGF-BB, IP-10), так и уменьшения (MCP-1, RANTES) уровня хемокинов и факторов роста в условиях РТК. Кроме общих количественных изменений кишечной микробиоты, уровня исследуемых веществ, установлена статистически значимая зависимость от пола, возраста пациента, а также степени дифференцировки и формы роста опухоли.</p></sec><sec><title>Заключение</title><p>Заключение. Установлено, что изменения количественного состава кишечной микробиоты, уровня некоторых биологически активных веществ, возникающие именно в условиях РТК, могут быть взаимосвязаны и взаимозависимы, а также служить дополнительным диагностическим маркёром при выявлении злокачественной опухоли. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. The incidence of colon cancer over the past decade has been growing markedly in the Russian Federation, with about 50 % cases detected at stagesIII–IV of the disease, when a clear clinical picture of the disease appears. In this regard, the search for new methods for early diagnosis of RTK is undoubtedly relevant.</p></sec><sec><title>Objective</title><p>Objective. To determine the standard composition of the aerobic parietal colon microbiota and the level of cytokines (chemokines and growth factors) in patients with cancer of the left half of the colon and to assess the possibility of using these data in the diagnosis of the tumor process.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Blood tests were performed on the day of the study using two test systems (BioLegend): multiplex kit for determining growth factors, chemokine multiplex kit. The composition of the intestinal microbiota was determined in colon biopsy specimens by the bacteriological method using the standard test systems StaphyTest, StreptoTest, and EnteroTest.</p></sec><sec><title>Results</title><p>Results. There is an increase in the number of Clostridiumspp. and a decrease in Bifidobacteriumspp., E. coli in the colon during the transformation of a healthy person’s mucosa into a malignant tumor (p &lt; 0.05); a clear tendency was revealed for both an increase (EGF, HGF, M-CSF, PDGF-AA, PDGF-BB, IP-10) and a decrease (MCP-1, RANTES) of the level of chemokines and growth factors under colon cancer conditions. In addition to general quantitative changes in the intestinal microbiota, the level of the investigated substances, a statistically significant dependence was established on the sex, age of the patient, as well as the degree of differentiation and form of tumor growth.</p></sec><sec><title>Conclusion</title><p>Conclusion. It was established that changes in the quantitative composition of the intestinal microbiota, the level of some biologically active substances that occur precisely in the conditions of colon cancer, can be interconnected and interdependent, and also serve as an additional diagnostic marker in the detection of a malignant tumor. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак толстой кишки</kwd><kwd>хемокины</kwd><kwd>факторы роста</kwd><kwd>диагностические маркеры</kwd><kwd>кишечная микробиота</kwd><kwd>биоптат толстой кишки</kwd><kwd>опухолевая ткань</kwd></kwd-group><kwd-group xml:lang="en"><kwd>colon cancer</kwd><kwd>chemokines</kwd><kwd>growth factors</kwd><kwd>diagnostic markers</kwd><kwd>intestinal microbiota</kwd><kwd>colon biopsy specimen</kwd><kwd>tumor tissue</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hernández-Luna MA, López-Briones S, LuriaPérez R. The four horsemen in colon cancer. J Oncol. 2019; doi: 10.1155/2019/5636272</mixed-citation><mixed-citation xml:lang="en">Hernández-Luna  MA, López-Briones  S, LuriaPérez  R. The  four horsemen in  colon cancer. J Oncol. 2019; doi: 10.1155/2019/5636272</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bahmani S, Azarpira N, Moazamian E. Anti-colon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742. Turk J Gastroenterol. 2019; 30(9): 835-842. doi: 10.5152/tjg.2019.18451</mixed-citation><mixed-citation xml:lang="en">Bahmani S, Azarpira N, Moazamian E. Anti-colon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742. Turk J Gastroenterol. 2019; 30(9): 835-842. doi: 10.5152/tjg.2019.18451</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kistner L, Doll D, Holtorf A, Nitsche U, Janssen KP. Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. Oncotarget. 2017; 8(52): 89998-90012. doi: 10.18632/oncotarget.21286</mixed-citation><mixed-citation xml:lang="en">Kistner L, Doll D, Holtorf A, Nitsche U, Janssen KP. Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. Oncotarget. 2017; 8(52): 89998-90012. doi: 10.18632/oncotarget.21286</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De la Fuente López M, Landskron G, Parada D, Dubois-Camacho K, Simian D, Martinez M, et al. The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer. Tumour Biol. 2018; 40(11): 1010428318810059. doi: 10.1177/1010428318810059</mixed-citation><mixed-citation xml:lang="en">De  la  Fuente López  M, Landskron  G, Parada  D, Dubois-Camacho  K, Simian  D, Martinez  M, et  al. The  relationship between chemokines CCL2, CCL3, and CCL4 with  the  tumor microenvironment and tumor-associated macrophage markers in colorectal cancer. Tumour Biol. 2018; 40(11): 1010428318810059. doi: 10.1177/1010428318810059</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Üçüncü M, Serilmez M, Sarı M, Bademler S, Karabulut S. The diagnostic significance of PDGF, EphA7, CCR5, and CCL5 levels in colorectal cancer. Biomolecules. 2019; 9(9): 464. doi: 10.3390/biom9090464</mixed-citation><mixed-citation xml:lang="en">Üçüncü M, Serilmez M, Sarı M, Bademler S, Karabulut S. The diagnostic significance of PDGF, EphA7, CCR5, and CCL5 levels in colorectal cancer. Biomolecules. 2019; 9(9): 464. doi: 10.3390/biom9090464</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Krzystek-Korpacka M, Zawadzki M, Kapturkiewicz B, Lewandowska P, Bednarz-Misa I, Gorska S, et al. Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine. 2018; 110: 435-441. doi: 10.1016/j.cyto.2018.05.015</mixed-citation><mixed-citation xml:lang="en">Krzystek-Korpacka M, Zawadzki M, Kapturkiewicz B, Lewandowska P, Bednarz-Misa I, Gorska S, et al. Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine. 2018; 110: 435-441. doi: 10.1016/j.cyto.2018.05.015</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lian G, Chen S, Ouyang M, Li F, Chen L, Yang J. Colon cancer cell secretes EGF to promote M2 polarization of TAM through EGFR/PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 2019; 18: 1533033819849068. doi: 10.1177/1533033819849068</mixed-citation><mixed-citation xml:lang="en">Lian G, Chen S, Ouyang M, Li F, Chen L, Yang J. Colon cancer cell secretes EGF to promote M2 polarization of TAM through EGFR/PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 2019; 18: 1533033819849068. doi: 10.1177/1533033819849068</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Herrera A, Herrera M, Guerra-Perez N, Galindo-Pumariño C, Larriba MJ, García-Barberán V, et al. Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1. Oncogenesis. 2018; 7(9): 76. doi: 10.1038/s41389-018-0085-z</mixed-citation><mixed-citation xml:lang="en">Herrera A, Herrera M, Guerra-Perez N, Galindo-Pumariño C, Larriba  MJ, García-Barberán V, et  al. Endothelial cell activation on  3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1. Oncogenesis. 2018; 7(9): 76. doi: 10.1038/s41389-018-0085-z</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sheng QS, He KX, Li JJ, Zhong ZF, Wang FX, Pan LL, et al. Comparison of gut microbiome in human colorectal cancer in paired tumor and adjacent normal tissues. Onco Targets Ther. 2020; 13: 635-646. doi: 10.2147/OTT.S218004</mixed-citation><mixed-citation xml:lang="en">Sheng QS, He KX, Li JJ, Zhong ZF, Wang FX, Pan LL, et al. Comparison of  gut microbiome in  human colorectal cancer in paired tumor and adjacent normal tissues. Onco Targets Ther. 2020; 13: 635-646. doi: 10.2147/OTT.S218004</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zorron Cheng Tao Pu L, Yamamoto K, Honda T, Nakamura M, Yamamura T, Hattori S, et al. Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon. JGastroenterol Hepatol. 2020; 35(3): 433-437. doi: 10.1111/jgh.14868</mixed-citation><mixed-citation xml:lang="en">Zorron Cheng Tao Pu L, Yamamoto K, Honda T, Nakamura M, Yamamura T, Hattori S, et al. Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon. JGastroenterol Hepatol. 2020; 35(3): 433-437. doi: 10.1111/jgh.14868</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sinha A, Kumar S. Prognostic value of Epidermal growth factor receptor in colorectal carcinoma. J Clin Diagn Res. 2018; 12(3): 1-4. doi: 10.7860/JCDR/2018/34864.11234</mixed-citation><mixed-citation xml:lang="en">Sinha A, Kumar S. Prognostic value of Epidermal growth factor receptor in  colorectal carcinoma. J Clin Diagn Res. 2018; 12(3): 1-4. doi: 10.7860/JCDR/2018/34864.11234</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mouzakiti A, Nastos C, Vlachodimitropoulos D, Gennatas C, Kondi-Pafiti A, Voros D. Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population. J BUON. 2018; 23(1): 23-28.</mixed-citation><mixed-citation xml:lang="en">Mouzakiti  A, Nastos  C, Vlachodimitropoulos  D, Gennatas C, Kondi-Pafiti A, Voros D. Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population. J BUON. 2018; 23(1): 23-28.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
